Allergic rhinitis (AR) is a chronic inflammatory disease that affects the nasal mucosa. The condition is caused by immunoglobin E (IgE) – mediated early-phase and late-phase hypersensitivity responses. Common symptoms of the disease are a blocked nasal passage, irritation and itchiness, repetitive sneezing, and rhinorrhea (a runny nose).
If the disease is not treated or managed effectively, it can have a lasting impact on a person’s quality of life, including their wellbeing, sleep pattern, and productivity.
Allergic rhinitis has a significant impact on quality of life if undiagnosed.
The report Allergic Rhinitis: Epidemiology Forecast to 2028 explores and discusses AR cases by taking key data to build a bigger picture of AR epidemiology, and the total prevalent cases of AR in the seven major markets (7MM): the US, France, Germany, Italy, Spain, the UK and Japan.
GlobalData projects an increase in diagnosed incident cases of AR in the 7MM from 5,621,030 in 2018 to 5,660,994 in 2028, at an annual growth rate of 0.07%. It has been found that AR is more common in women and younger age groups.
The key points of this report include:
- Full epidemiology report and overview
- A 10-year forecast for diagnosed incident cases
- Market-driven analysis to indicate trends in the AR market
- A breakdown of common allergens and their relationship with disease
This report provides insight into the AR market and enables the reader to understand the magnitude of severity. Readers can also explore and utilise data to identify key commercial opportunities and create strategies for success in the AR market. Using key pharmaceutical data and analysis, companies will be able to make better decisions in the pursuit of drug development.
To find more information about this and other reports, visit the GlobalData Report Store.